PLC Pall Corp

     
BW20021223002097  20021223T132112Z UTC


( BW)(PALL-CORPORATION)(PLC) Acquisition

    Business Editors
    UK REGULATORY NEWS

    EAST HILLS, N.Y.--(BUSINESS WIRE)--Dec. 23, 2002--

    Pall Corporation Announces the Purchase of Whatman HemaSure Inc. 
    Assets

Pall Corporation (NYSE: PLL) today announced the signing of an
Asset Purchase Agreement with Whatman HemaSure Inc., a wholly owned
subsidiary of Whatman plc (LSE: WHM.L). The parties further agreed to
settle all disputes between the companies concerning Pall's patents
for leukodepleting filters and systems and the Whatman HemaSure
LeukoNet and rLS series of filters. This $5,950,000 transaction is
expected to close in January 2003.

The parties were involved in ongoing litigation in New York and
Colorado, with Pall asserting infringement of claims from a number of
its patents. Under the terms of Stipulations, to be filed in the New
York and Colorado cases, Whatman has acknowledged the validity and
enforceability of the asserted claims of those Pall patents. In the
same Stipulations, Pall has consented to dismiss all patent-related
claims against the Whatman companies in both the New York and Colorado
cases.

Eric Krasnoff, Chairman and CEO of Pall Corporation said, "Pall
and Whatman have agreed to work together in the best interests of the
blood banking community to ensure an orderly market transition. This
purchase is not expected to affect our earnings for the year."

About Pall Corporation:

Pall Corporation is the global leader in the rapidly growing
filtration, separations and purification industry. Pall's business is
organized around two broad markets: Life Sciences and Industrial. The
Company provides leading-edge products to meet the demanding needs of
customers in biotechnology, pharmaceuticals, transfusion medicine,
semiconductors, municipal drinking water and aerospace. Total revenues
are $1.3 billion. The Company is headquartered in East Hills, New York
and has major operations in more than 30 countries. Further
information is available at http://www.pall.com.

This release contains "forward-looking statements" as defined in
the Private Securities Litigation Reform Act of 1995. These statements
are based on current Company expectations and are subject to risks and
uncertainties, which could cause actual results to differ materially.
Such risks and uncertainties include, but are not limited to:
fluctuations in foreign currency exchange rates; regulatory approval
and market acceptance of new technologies; changes in product mix and
product pricing and in interest rates and cost of raw materials; the
Company's success in enforcing its patents and protecting its
proprietary products and manufacturing techniques and in integrating
the operations of FSG into the Company's existing business; global and
regional economic conditions and legislative, regulatory and political
developments; and domestic and international competition in the
Company's global markets. Additional information regarding these and
other factors is available on the web at http://www.pall.com and is
included in the Company's reports filed with the U.S. Securities and
Exchange Commission. Copies of such reports can be obtained, without
charge, at: http://www.sec.gov.

    
   Short Name: Pall Corporation
   Category Code: ACQ
   Sequence Number: 00001482
   Time of Receipt (offset from UTC): 20021220T215828+0000

    --30--EB/ny 

    CONTACT: Pall Corporation
             Diane Foster, 516/801-9102
             dfoster@pall.com

    KEYWORD: NEW YORK UNITED KINGDOM INTERNATIONAL EUROPE
    INDUSTRY KEYWORD: BIOTECHNOLOGY MEDICAL MEDICAL DEVICES 
PHARMACEUTICAL MERGERS/ACQ               
    SOURCE: Pall Corporation

Today's News On The Net - Business Wire's full file on the Internet
                          with Hyperlinks to your home page.
                          URL: http://www.businesswire.com

Pall Corp (LSE:PLC)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024

Pall Corp (LSE:PLC)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024